Seasonal temperature is associated with Parkinson’s disease prescriptions: an ecological study
The aim of this study is to test what effect the weather may have on medications prescribed to treat Parkinson’s disease. Twenty-three years of monthly time, series data was sourced from the Pharmaceutical Benefits Scheme (PBS) and the Bureau of Meteorology (BOM). Data were available for eight states and territories and their corresponding capital cities. The dependent variable was the aggregate levodopa equivalent dose (LED) for 51 Parkinson’s medications identified on the PBS. Two explanatory variables of interest, temperature and solar exposure, were identified in the BOM data set. Linear and cosinor models were estimated with fixed and random effects, respectively. The prescribed LED was 4.2% greater in January and 4.5% lower in July. Statistical analysis showed that temperature was associated with the prescription of Parkinson medications. Our results suggest seasonality exists in Parkinson’s disease symptoms and this may be related to temperature. Further work is needed to confirm these findings and understand the underlying mechanisms as a better understanding of the causes of any seasonal variation in Parkinson’s disease may help clinicians and patients manage the disease more effectively.
KeywordsParkinson’s disease Seasonality Temperature
We would like to thank Dr. Douglas Rowell for his assistance with interpreting the meteorological data.
No external funding was provided for this research.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Australian Bureau of Statistics (2008) Year book Australia 2008 ABS Catalogue No. 1301.0. ABS, CanberraGoogle Scholar
- Barnett AG, Dobson AJ (2010) Analysing seasonal health data, vol 30. SpringerGoogle Scholar
- Bureau of Meteorology (2016) Climate data online. Commonwealth of Australia http://www.bom.gov.au/climate/data/?ref=ftr. Accessed June 2015
- Deloitte Access Economics (2015) Living with Parkinson’s Disease: An updated economic analysis 2014. Report prepared for Parkinson’s Australia. DeloitteGoogle Scholar
- Eisen A, Calne D (1992) Amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease: phylogenetic disorders of the human neocortex sharing many characteristics. Can J Neurol Sci/Journal Canadien des Sciences Neurologiques 19(S1):117–123Google Scholar
- Miura T, Shimura M, Kimura T (1987) Season of birth in parkinsonism. Prog Biometeorol 6:157–162Google Scholar
- Nair R, Maseeh A (2012) Vitamin D: the “sunshine” vitamin. J Pharmacol Pharmacother 3(2):118Google Scholar
- Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/Mds.23429
- van Gool K, Parkinson B, Kenny P (2011) Medicare Australia data for research: an introduction Centre for Health Economics Research and Evaluation (CHERE), SydneyGoogle Scholar
- Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ (1991) Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA. Chin Med J 104(11):960–964Google Scholar
- Wooldridge JM (2000) Introductory econometrics: a modern approach. Southern-Western College Publishing, USAGoogle Scholar